George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarillion Plc Regulatory News (CLLN)

  • This share is currently suspended. It was suspended at a price of 14.27

Share Price Information for Carillion Plc (CLLN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.27
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.27
CLLN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

29 Sep 2017 07:00

RNS Number : 2047S
Carillion PLC
29 September 2017
 

 

 

 

 

 

 

 

29 September 2017

Financial results for the six months ended 30 June 2017

Strategic and operational review update

 

Carillion plc ("Carillion", the "Group" or the "Company") announces its H1 results and an update on its strategic review.

 

H1 financial performance weaker

· Total revenue flat at £2.5bn

· Underlying pre-tax profit down 40% due to:

- The phasing of PPP equity disposals; and

- The trading of contracts with H1 provisions at zero margin

· Contracts review finalised:

- No change to previously announced provision of £845m for construction contracts

- Further £200m provision for support services contracts, but minimal impact on cash

· Goodwill impairment charge of £134m in respect of UK and Canadian construction businesses

· Average net debt in H1 £694m

· New H1 orders plus probable orders of £2.6bn, with total orders plus probables stable at £16bn

 

H1 2017

H1 2016

Total Underlying Revenue

£2,498m

£2,487m

Underlying profit from operations

£82m

£112m

Underlying operating margin1

3.5%

4.9%

Underlying profit before taxation1

£50m

£85m

Underlying earnings per share1

9.6p

16.0p

(Loss)/profit before taxation

£(1,153)m

£84m

Basic (loss)/earnings per share

(261.2)p

15.8p

Net debt

£571m

£291m

 

Strategic review and balance sheet update

· Business refocused on core strengths and markets - support services, infrastructure and building

· New leadership team and operating model - delayered structure, greater accountability and transparency

· Initial cost reduction target of £75m by mid-2019

· Actions underway to improve cash flow and strengthen balance sheet

· Expected proceeds from non-core business disposals increased to £300m from £125m

· Discussions ongoing regarding sales of Carillion's business in Canada and the UK Healthcare business

· Pension deficit reduction of £80m, potential to reduce further by £120m

· Agreed further £140m committed facility with a number of banks

Revised full-year outlook

· Full-year results to be lower than current market expectations

· Total revenue expected to be between £4.6bn and £4.8bn (previously £4.8bn to £5.0bn)

· 2017 H1/H2 profit split similar to recent years, before £10m of cost savings and business disposals

· Full-year average net debt expected to be between £825m and £850m

· Estimated further restructuring costs of £75m to £100m in H2.

Commenting Keith Cochrane, Interim Chief Executive, said:

 

"This is a disappointing set of results which reflects the issues we flagged in July and the additional £200m provision for our Support Services business that we have announced today. We now expect results for the full year to be lower than current market expectations.

 

"The Strategic Review that we launched in July has enabled us to get a firm handle on the Group's problems and we have implemented a clear plan to address them. Our objective is to be a lower risk, lower cost, higher quality business generating sustainable cash backed earnings. In the immediate short term, our focus is to complete the disposal programme, accelerate our action to take cost out of the business and get our balance sheet back to a place where it can support Carillion going forward.

 

"No one is in any doubt of the challenge that lies ahead. We have made an encouraging start and the ambition is there to build on that progress. At the heart of this company, there is a strong core. Supported by an operating model that manages risk much more effectively and led by a fresh management team with a mandate to drive cultural change, I am confident that a strong business can emerge."

 

A presentation for institutional investors and analysts will be held today starting at 09:00. The presentation will be webcast live on www.carillionplc.com and subsequently available on demand. A dial-in facility is also available on 0808 109 0700 (UK Toll Free) or +44 (0) 20 3003 2666 (Standard International Access) with a participant pin code of 1209521# and a password of ' Carillion'. A replay facility will be available for 7 days on +44 (0) 20 8196 1998 with an access code of 1209521#, password 'Carillion'.

 

This announcement contains inside information.

 

For further information contact:

 

Institutional Investors and Analysts

John Denning, Group Corporate Affairs Director

Kellie McAvoy, Head of Investor Relations

tel: +44 (0) 1902 906333

 

 

Media

Charlie Armitstead/Haya Herbert-Burns

Teneo Blue Rubicon

tel: +44 (0) 207 420 3197

 

 

 

29 September 2017

 

This and other Carillion news releases can be found at www.carillionplc.com.

 

Cautionary statement

This announcement may contain indications of likely future developments and other forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. These and other factors could adversely affect the Group's results, strategy and prospects. Forward-looking statements involve risks, uncertainties and assumptions. They relate to events and/or depend on circumstances in the future which could cause actual results and outcomes to differ materially from those currently anticipated. No obligation is assumed to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

To view the full Interim Results please click on the link below

 

http://www.rns-pdf.londonstockexchange.com/rns/2047S_1-2017-9-29.pdf

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EASNNAAPXEEF
Date   Source Headline
3rd Apr 20187:30 amRNSUpdate re Liquidation of Carillion
19th Mar 20187:00 amRNSFRC investigation
17th Jan 20188:15 amRNSAnnouncement Re. Carillion PLC
15th Jan 20187:45 amRNSSuspension - Carillion PLC
15th Jan 20187:00 amRNSCompulsory liquidation of Carillion
12th Jan 20186:08 pmRNSUpdate on discussions with creditors
12th Jan 20185:08 pmRNSHolding(s) in Company
10th Jan 20185:48 pmRNSHolding(s) in Company
9th Jan 20187:03 amRNSResponse to share price movement
3rd Jan 20184:44 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSRegulatory investigation
22nd Dec 20177:00 amRNSUpdate on financial covenant deferral
20th Dec 201710:16 amRNSBlock listing Interim Review
20th Dec 20177:00 amRNSChief Executive Appointment
13th Dec 20177:00 amRNSUpdate on UK healthcare facilities business
11th Dec 20177:58 amRNSHolding(s) in Company
1st Dec 20177:00 amRNSDirectorate Change
23rd Nov 201712:08 pmRNSHolding(s) in Company
22nd Nov 201712:29 pmRNSHolding(s) in Company
21st Nov 20174:11 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFramework Award
17th Nov 20177:02 amRNSUpdate
15th Nov 20177:00 amRNSOman - letter of award for contract
6th Nov 20177:00 amRNSContract wins
2nd Nov 20177:00 amRNSDirectorate Change
31st Oct 20177:00 amRNSDisposal
27th Oct 20177:00 amRNSChief Executive Appointment
24th Oct 20177:00 amRNSUpdate on financing, disposals and work winning
12th Oct 201712:43 pmRNSUK Healthcare business
4th Oct 20172:58 pmRNSHolding(s) in Company
29th Sep 20177:00 amRNSHalf-year Report
22nd Sep 20171:00 pmRNSHolding(s) in Company
19th Sep 20174:55 pmRNSHolding(s) in Company
11th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:17 pmRNSAnnouncement of 2017 interim results
17th Aug 20174:19 pmRNSHolding(s) in Company
15th Aug 20175:58 pmRNSHolding(s) in Company
11th Aug 20176:20 pmRNSHolding(s) in Company
8th Aug 20173:59 pmRNSHolding(s) in Company
8th Aug 201710:02 amRNSHolding(s) in Company
3rd Aug 20179:02 amRNSHolding(s) in Company
1st Aug 201712:24 pmRNSHolding(s) in Company
31st Jul 20172:57 pmRNSHolding(s) in Company
27th Jul 20176:28 pmRNSHolding(s) in Company
18th Jul 201710:49 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSCarillion JV awarded two further HESTIA contracts
17th Jul 20177:19 amRNSHS2 Contract Award
17th Jul 20177:00 amRNSCarillion appoints EY to support strategic review
14th Jul 201712:20 pmRNSHolding(s) in Company
14th Jul 20177:00 amRNSAppointment of Joint Financial Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.